Result:Poor· Market: Flat#Margin squeeze
| Metric | Value (₹ Cr) | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue | 26.58 | 37.1% | 23.2% |
| Total Income | 28.49 | 35.2% | 19.1% |
| Expenditure | 28.42 | 31.3% | 10.7% |
| PBT | 0.08 | 97.1% | 97.8% |
| Net Profit | 0.08 | 97.3% | 97.8% |
| OPM | 3.32% | 5.08pp | 11.32pp |
| NPM | 0.26% | 5.99pp | 9.36pp |
| EPS | 0.03 | 97.4% | 97.9% |
Revenue fell 23% YoY and OPM collapsed from 14.6% to 3.3%, wiping out PAT by 98% to near-breakeven — a clear deterioration in the core pharma business, not a one-off.
Informational and educational content only. Not investment advice.